Lilly-linked brain metastases trial posts results; two baricitinib studies complete

Four items touched Lilly's registry footprint this week, ranging from a completed oncology study with posted results to two completed dermatology studies where Lilly serves as a collaborator.

• A Phase 2 genomically-guided trial in patients with brain metastases, sponsored by the Alliance for Clinical Trials in Oncology with Lilly and several other companies as collaborators, posted results on 2026-10-30. The study tested how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain, using targeted drugs such as abemaciclib, paxalisib, entrectinib and adagrasib against mutations including NTRK, ROS1, CDK, PI3K, or KRAS G12C¹, with actual enrollment of 50 participants¹.
• Lilly's Phase 3 eloralintide (LY3841136) study, acronym ENLIGHTEN-10, remains not yet recruiting. The trial is a randomized, double-blind, placebo-controlled study evaluating eloralintide against placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk², with enrollment estimated at 3000 participants².
• A Phase 4 study of baricitinib for frontal fibrosing alopecia, sponsored by the University of Alabama at Birmingham with Lilly as a collaborator, is listed as completed. The trial enrolled 20 participants³ and tracked the percentage of patients achieving a 30% change in Lichen Planopilaris Activity (LPPAI) scores³ as its primary outcome.
• A Phase 2 study of baricitinib for oral lichen planus, sponsored by the University of North Carolina, Chapel Hill with Lilly as a collaborator, is also listed as completed. The study enrolled 10 participants⁴ and measured change in Oral Disease Severity Scale (ODSS) scores from baseline to 24 weeks⁴ as its primary outcome.